Ratings by Raymond James (Chris Raymond)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/3/2026 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/28/2026 | Tyra Biosciences | TYRA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/13/2026 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/13/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/12/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/8/2026 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/7/2026 | Monopar Therapeutics | MNPR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Taysha Gene Therapies | TSHA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/5/2026 | Sionna Therapeutics | SION | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/2/2026 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/30/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/12/2025 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/11/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/8/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/3/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Strong Buy (N/A) |
9.52 (5.85) |
-38.55% | Details | |
| 11/25/2025 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/20/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2025 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/14/2025 | Monopar Therapeutics | MNPR | Downgrade | Outperform (Strong Buy) |
87.01 (57.61) |
-33.79% | Details | |
| 11/12/2025 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/11/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2025 | Sionna Therapeutics | SION | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/3/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/21/2025 | Taysha Gene Therapies | TSHA | New Coverage | Strong Buy (N/A) |
4.72 (4.57) |
-3.18% | Details | |
| 10/21/2025 | MeiraGTx Holdings plc | MGTX | New Coverage | Strong Buy (N/A) |
7.75 (7.00) |
-9.68% | Details | |
| 10/6/2025 | Monopar Therapeutics | MNPR | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/26/2025 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/22/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/2/2025 | Vertex | VRTX | New Coverage | Market Perform (N/A) |
391.02 (456.69) |
16.79% | Details | |
| 9/2/2025 | Tyra Biosciences | TYRA | New Coverage | Strong Buy (N/A) |
12.67 (35.04) |
176.56% | Details | |
| 9/2/2025 | Sionna Therapeutics | SION | New Coverage | Strong Buy (N/A) |
24.62 (35.93) |
45.94% | Details | |
| 9/2/2025 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
76.58 (99.41) |
29.81% | Details | |
| 9/2/2025 | Monopar Therapeutics | MNPR | New Coverage | Strong Buy (N/A) |
34.15 (87.01) |
154.79% | Details | |
| 9/2/2025 | Kalaris | KLRS | New Coverage | Strong Buy (N/A) |
4.08 (9.82) |
140.69% | Details | |
| 9/2/2025 | Cogent | COGT | New Coverage | Strong Buy (N/A) |
12.08 (37.08) |
206.95% | Details | |
| 9/2/2025 | Ardelyx, Inc | ARDX | New Coverage | Strong Buy (N/A) |
6.36 (6.19) |
-2.67% | Details | |
| 9/2/2025 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
287.71 (369.53) |
28.44% | Details | |
| 9/2/2025 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
58.27 (61.12) |
4.89% | Details | |
| 9/2/2025 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Strong Buy (N/A) |
15.39 (9.92) |
-35.54% | Details | |
| 9/2/2025 | Regeneron Pharma | REGN | New Coverage | Outperform (Market Perform) |
580.70 (759.86) |
30.85% | Details |
